TY  - JOUR
A1  - Mücke, Victoria Therese
A1  - Jakobi, Katja
A1  - Knop, Viola
A1  - Thomas, Dominique Jeanette
A1  - Mücke, Marcus Maximilian
A1  - Peiffer, Kai-Henrik
A1  - Zeuzem, Stefan
A1  - Sarrazin, Christoph
A1  - Pfeilschifter, Josef
A1  - Grammatikos, Georgios
T1  - Serum sphingolipid levels associate with upcoming virologic events and HBV genotype D in a cohort of patients with HBeAg-negative HBV infection
T2  - PLoS one
N2  - Objectives: Sphingolipids (SLs) have been implicated as potent regulators of the hepatitis B virus (HBV) life cycle. We investigated the SL biomarker potential regarding virologic endpoints in a prospective subgroup of patients with HBeAg-negative chronic HBV infection.
Methods: From 2009–2016 98 patients with HBeAg-negative HBV infection were prospectively followed over four years. Clinical, laboratory and imaging data were evaluated annually. SLs were assessed in available serum probes via liquid chromatography coupled to tandem mass spectrometry.
Results: Of those 98 patients, 10 (10.2%) showed HBV reactivation, 13 (13.2%) lost HBsAg and 9 (9.1%) gained status of HBsAg-/HBsAb-coexistence, whereas 66 (67.3%) had no events. Within the four-year analysis sphingosine (p = 0.020), sphinganine (p<0.001), dhS1P (p<0.001), C16DHC (p<0.01) and C20Cer (p<0.001) showed a significant upregulation in patients without virologic events, C18Cer significantly decreased (p<0.001). At baseline decreased S1P-, dhS1P- and C16Cer-levels were observed in patients with upcoming status of HBsAg-/HBsAb-coexistence. S1P and dhS1P levels were elevated HBV genotype D infected patients.
Conclusions: In a prospective cohort of patients with a HBeAg-negative HBV infection, serum SLs associated with the virologic course and HBV genotype D. Further studies are required to elucidate SLs as potential novel predictors of the course of HBeAg-negative HBV infection.
KW  - Hepatitis B virus
KW  - Sphingolipids
KW  - Viral load
KW  - Hepatocellular carcinoma
KW  - Liver fibrosis
KW  - Transferases
KW  - Fibrosis
KW  - Antiviral therapy
Y1  - 2018
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/47846
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-478468
SN  - 1932-6203
N1  - Copyright: © 2018 Mücke et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
VL  - 13
IS  - (11): e0207293
SP  - 1
EP  - 17
PB  - PLoS
CY  - Lawrence, Kan.
ER  -